Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, announced Wednesday that it has acquired BrainVectis, a Paris-based gene therapy company and French National Institute for Health and Medical Research (INSERM) spin-out with expertise and an intellectual property estate for the treatment of neurodegenerative disorders. BrainVectis is particularly focused on therapies that restore brain cholesterol metabolism as a treatment for Huntington’s disease and other disorders. Financial terms of the acquisition were not disclosed.
Read the full article: AskBio Acquires BrainVectis to Expand Its Clinical Pipeline for Neurodegenerative Diseases //
Source: https://www.globenewswire.com/news-release/2020/04/22/2019940/0/en/AskBio-Acquires-BrainVectis-to-Expand-its-Clinical-Pipeline-for-Neurodegenerative-Diseases.html